Stonehill Capital Management’s Trinity Biotech TRIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-248,399
Closed -$507K 11
2024
Q1
$507K Sell
248,399
-54,196
-18% -$127K 1.14% 5
2023
Q4
$649K Hold
302,595
1.28% 7
2023
Q3
$1.11M Hold
302,595
1.76% 6
2023
Q2
$1.44M Sell
302,595
-15,000
-5% -$72.6K 0.85% 7
2023
Q1
$1.49M Sell
317,595
-16,935
-5% -$87.3K 0.77% 8
2022
Q4
$1.66M Sell
334,530
-79,119
-19% -$479K 1.79% 7
2022
Q3
$2.21M Sell
413,649
-40,494
-9% -$261K 1.8% 11
2022
Q2
$2.78M Hold
454,143
1.85% 11
2022
Q1
$2.41M Buy
454,143
+410,154
+932% +$2.36M 1.12% 12
2021
Q4
$315K Sell
43,989
-53,798
-55% -$508K 0.07% 22
2021
Q3
$1.06M Hold
97,787
0.5% 14
2021
Q2
$1.44M Hold
97,787
0.7% 14
2021
Q1
$1.84M Sell
97,787
-100,736
-51% -$2.42M 0.86% 10
2020
Q4
$3.78M Sell
198,523
-74,397
-27% -$1.23M 1.15% 12
2020
Q3
$2.76M Sell
272,920
-208,527
-43% -$2.41M 1.49% 10
2020
Q2
$5.25M Sell
481,447
-119,067
-20% -$907K 1.37% 12
2020
Q1
$3.3M Hold
600,514
1.09% 16
2019
Q4
$3.1M Buy
600,514
+27,938
+5% +$133K 1.06% 11
2019
Q3
$3.46M Buy
572,576
+110,385
+24% +$959K 0.94% 11
2019
Q2
$3.81M Buy
462,191
+130,748
+39% +$1.55M 1.09% 7
2019
Q1
$4.72M Buy
331,443
+3,674
+1% +$50.5K 1.42% 10
2018
Q4
$3.75M Buy
327,769
+153,360
+88% +$2.37M 1.75% 15
2018
Q3
$3.49M Buy
174,409
+26,643
+18% +$579K 1.32% 14
2018
Q2
$3.69M Hold
147,766
1.45% 10
2018
Q1
$3.81M Hold
147,766
1.63% 7
2017
Q4
$3.77M Hold
147,766
1.53% 10
2017
Q3
$4.14M Hold
147,766
1.65% 8
2017
Q2
$4.43M Hold
147,766
1.68% 10
2017
Q1
$4.4M Hold
147,766
1.93% 13
2016
Q4
$5.11M Buy
+147,766
New +$5.09M 2.59% 11

Other funds holding TRIB

Stonehill Capital Management's TRIB Position: Q2 2024 in Review

Stonehill Capital Management sold out of Trinity Biotech (TRIB) in Q2 2024, closing a stake of 248,399 shares — an estimated $507K sold.

Stonehill Capital Management first reported a position in TRIB in Q4 2016 and held it in 30 quarters. The position peaked at $5.25M in Q2 2020. 20 funds tracked by Wall St. Rank hold TRIB as of Q2 2024.

  • Stonehill Capital Management reported no remaining Trinity Biotech position as of Q2 2024 after selling out during the quarter.
  • Stonehill Capital Management sold 248,399 Trinity Biotech shares in Q2 2024, an estimated $507K.
  • Stonehill Capital Management first reported a position in Trinity Biotech in Q4 2016 and held it in 30 quarters.
  • Stonehill Capital Management's Trinity Biotech position peaked at $5.25M in Q2 2020.
  • 20 funds tracked by Wall St. Rank held Trinity Biotech as of Q2 2024.

Based on Stonehill Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.